 Study Population: Five participants with active anterior uveitis will be initially accrued in this study. Participants must require treatment for their uveitis with systemic andor topical anti-inflammatory medications at high frequency intervals greater than or equal to three times daily T.I.D. or local steroid treatment periocular steroid injections is contraindicated because of significant intraocular pressure IOP elevation with local steroid treatments in the past i.e., steroid responder, have at least a grade of 1 for anterior chamber cells and have visual acuity of at least 20400 in the study eye. Up to seven participants may be enrolled, as up to two participants may be accrued to replace enrolled participants who withdraw from the study prior to receiving any study medication. 